NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 122 filers reported holding NURIX THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $415,724 | -21.2% | 52,891 | +0.1% | 0.00% | – |
| Q2 2023 | $527,742 | +66.5% | 52,827 | +47.8% | 0.00% | – |
| Q1 2023 | $317,000 | +32280.0% | 35,735 | -59.9% | 0.00% | – |
| Q4 2022 | $979 | -99.7% | 89,096 | +215.1% | 0.00% | – |
| Q3 2022 | $368,000 | -77.6% | 28,274 | -78.2% | 0.00% | – |
| Q2 2022 | $1,641,000 | -2.8% | 129,525 | +7.5% | 0.00% | – |
| Q1 2022 | $1,688,000 | -35.1% | 120,516 | +34.1% | 0.00% | – |
| Q4 2021 | $2,601,000 | +49.7% | 89,852 | +55.0% | 0.00% | – |
| Q3 2021 | $1,737,000 | +127.1% | 57,985 | +101.1% | 0.00% | – |
| Q2 2021 | $765,000 | +106.8% | 28,837 | +142.3% | 0.00% | – |
| Q1 2021 | $370,000 | +115.1% | 11,899 | +127.5% | 0.00% | – |
| Q4 2020 | $172,000 | +24.6% | 5,231 | +26.4% | 0.00% | – |
| Q3 2020 | $138,000 | – | 4,140 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |